查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
分子腫瘤診斷市場 - 全球及區域分析：按產品、技術、應用、癌症類型、最終用戶和國家 - 分析與預測（2024-2033 年）
市場調查報告書
商品編碼
1697459

分子腫瘤診斷市場 - 全球及區域分析：按產品、技術、應用、癌症類型、最終用戶和國家 - 分析與預測（2024-2033 年）

Molecular Oncology Diagnostics Market - A Global and Regional Analysis: Focus on Product, Technology, Application, Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033
出版日期: | 出版商: BIS Research | 英文 171 Pages | 商品交期: 1-5個工作天內

價格

預計2024年全球分子腫瘤診斷市場規模將達24.109億美元。

預計到 2033 年市場規模將達到 61.951 億美元，複合年成長率為 11.06%。預計全球分子腫瘤診斷市場的成長將受到次世代定序、數位 PCR 和液態切片等分子診斷技術進步以及全球癌症盛行率上升的推動。然而，全球分子腫瘤診斷市場的擴張受到多重挑戰的阻礙。分子診斷測試的高成本仍然是一個主要障礙，特別是在醫療保健資金往往有限的中低收入國家。此外，接受過有效使用這些先進診斷工具的培訓的熟練專業人員明顯短缺，這進一步限制了成長。

儘管面臨這些挑戰，但在技術不斷進步的推動下，全球分子腫瘤診斷市場仍在持續成長。生物技術、製藥和學術機構之間的策略聯盟至關重要，可以促進創新並加速新診斷技術的開發和採用。克服成本和勞動力發展障礙是充分發揮分子診斷在改善全球癌症治療的潛力的關鍵。

主要市場統計數據
預測期 2024-2033
2024年評估 24.1億美元
2033年的預測 61.9億美元
複合年成長率 11.06%

全球分子腫瘤診斷市場正處於高級階段。分子腫瘤診斷生態系統正在經歷創新產品發布和監管核准的激增，推動癌症治療的重大進步。公司正在利用次世代定序(NGS)、液態切片和數位 PCR 等最尖端科技不斷開發新的診斷工具，以使癌症檢測和監測更加準確和有效率。這些創新對於提供個人化治療方案和改善患者治療效果至關重要。

預計未來幾年全球分子腫瘤診斷市場的擴張將主要受到各類癌症盛行率上升的推動。由於人口老化、久坐的生活方式和遺傳風險因素等因素，全球癌症發生率持續上升。 2022年，全球將有約2,000萬例新發癌症病例和970萬例癌症相關死亡病例。最常見的是肺癌，佔12.40%，其次是乳癌，佔11.60%。在預計預測期內，癌症發生率的上升和早期檢測重要性的增加將推動分子腫瘤診斷市場的成長。

基於產品，全球分子腫瘤診斷市場預計將由產品部分主導，因為套件和檢測試劑需求量大且成本低。

從技術角度來看，聚合酵素鏈鎖反應(PCR) 因其高靈敏度、準確性和成本效益而佔據全球分子腫瘤診斷市場主導地位。

根據應用，全球分子腫瘤診斷市場以臨床診斷為主。這一優勢歸因於精準醫療在醫療保健領域的日益普及，其中分子診斷對於識別特定的致癌突變以指導標靶治療決策至關重要。

根據癌症類型，全球分子腫瘤診斷市場以固體癌為主。這一優點是由於與骨髓惡性腫瘤相比，乳癌、肺癌和大腸癌等固體癌癌症的盛行率更高。固體癌是最常見的癌症之一，需要廣泛的診斷測試才能製定有效的治療計劃，因此該領域對分子診斷的需求增加。

根據最終用戶，全球分子腫瘤診斷市場由醫院部門主導。這主要是因為醫院是直接的患者護理機構，快速且準確的診斷測試對於及時做出癌症治療決策至關重要。

2023 年北美的銷售額累計9.696 億美元。由於幾個關鍵因素，北美分子腫瘤診斷市場有望大幅成長。還有預測稱，到 2050 年，固體癌和骨髓惡性腫瘤的發生率將大幅增加。此外，該地區擁有眾多全球和本地公司，從而提高了獲得先進診斷技術的管道。

本報告研究了全球分子腫瘤診斷市場，並概述了市場以及產品、技術、應用、癌症類型、最終用戶、國家和公司概況的趨勢。

目錄

執行摘要

第1章全球分子腫瘤診斷市場：產業展望

  • 全球癌症發生率和盛行率（按癌症類型分類）
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區
  • 趨勢：現況與未來影響評估
    • 加強參與企業間的夥伴關係
    • 增加分子腫瘤診斷生態系統中的創新產品發布和監管核准
  • 監管狀況
  • COVID-19 對分子腫瘤診斷市場的影響
  • 基於液態生物檢體的分子癌症診斷
  • 實驗室測試（LDT）和體外診斷（IVD）
  • 伴同性診斷在分子腫瘤診斷市場中的作用
  • 市場動態
    • 市場促進因素
    • 市場挑戰
    • 市場機會

2. 全球分子腫瘤診斷市場（按產品）

  • 產品摘要
  • 套件和檢測試劑
  • 裝置
  • 軟體

3. 全球分子腫瘤診斷市場（按技術）

  • 技術摘要
  • 聚合酵素鏈鎖反應
  • 次世代定序
  • 免疫組織化學
  • 螢光原位雜合技術
  • 流式細胞技術
  • 其他

4. 全球分子腫瘤診斷市場（按應用）

  • 使用摘要
  • 臨床診斷
  • 研究用途

第5章全球分子腫瘤診斷市場（依癌症類型）

  • 癌症類型摘要
  • 固態腫瘤
    • 乳癌
    • 肺癌
    • 大腸直腸癌
    • 攝護腺癌
    • 卵巢癌
    • 其他
  • 造血系統惡性腫瘤
    • 淋巴瘤
    • 白血病
    • 多發性骨髓瘤
    • 其他

6. 全球分子腫瘤診斷市場（依最終用戶）

  • 最終用戶摘要
  • 醫院和診斷中心
  • 參考實驗室
  • 製藥和生物技術公司
  • 學術研究所

7. 全球分子腫瘤診斷市場（按地區）

  • 區域摘要
  • 促進因素和約束因素
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

8. 全球分子腫瘤診斷市場競爭基準化分析與公司簡介

  • 關鍵策略發展
  • 企業市場占有率分析
  • 公司簡介
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Biocartis Group NV
    • bioMerieux
    • Bio-Rad Laboratories, Inc.
    • Danaher Corporation
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • Guardant Health, Inc.
    • Hologic, Inc.
    • Illumina, Inc.
    • Invivoscribe, Inc.
    • Myriad Genetics, Inc.
    • QIAGEN NV
    • Sysmex Corporation
    • Thermo Fisher Scientific, Inc.

第9章調查方法

Product Code: BHP1289SB

Global Molecular Oncology Diagnostics Industry Overview:

The global molecular oncology diagnostics market was valued at $2,410.9 million in 2024, and the market is expected to grow with a CAGR of 11.06% and reach $6,195.1 million by 2033. The growth in the global molecular oncology diagnostics market is expected to be driven by rising technological advancements in molecular diagnostics such as next-generation sequencing, digital PCR, and liquid biopsy, among others and the rising prevalence of cancers globally. However, the expansion of the global molecular oncology diagnostics market has been hindered by several challenges. The high cost of molecular diagnostic tests remains a major barrier, particularly in low- and middle-income countries where healthcare funding is often limited. Additionally, there has been a noticeable gap in the availability of skilled professionals who are trained to use these advanced diagnostic tools effectively, further restraining the growth.

Despite these challenges, the global molecular oncology diagnostics market continues to grow, driven by continuous technological advancements. Strategic collaborations between biotechnology companies, pharmaceutical firms, and academic institutions are vital, fostering innovation and accelerating the development and adoption of new diagnostic technologies. Overcoming the hurdles of cost and workforce training will be crucial for maximizing the potential of molecular diagnostics in improving cancer care globally.

KEY MARKET STATISTICS
Forecast Period2024 - 2033
2024 Evaluation$2.41 Billion
2033 Forecast$6.19 Billion
CAGR11.06%

Market Lifecycle Stage

The global molecular oncology diagnostics market is in progressive phase. The molecular oncology diagnostics ecosystem is witnessing a surge in the launch of innovative products and obtaining regulatory approvals, driving significant advancements in cancer care. Companies are continuously developing new diagnostic tools that leverage cutting-edge technologies such as next-generation sequencing (NGS), liquid biopsy, and digital PCR, which enhance the accuracy and efficiency of cancer detection and monitoring. These innovations are crucial in providing personalized treatment plans and improving patient outcomes.

Impact

The expansion of the global molecular oncology diagnostics market in the coming years will be primarily driven by the rising prevalence of cancer across all types. The global incidence of cancer continues to increase due to factors such as an aging population, sedentary lifestyles, and hereditary risk factors. In 2022, there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths worldwide. Lung cancer accounted for the highest share of total cancer cases at 12.40%, followed by breast cancer at 11.60%. The growing burden of cancer and the increasing emphasis on early detection are expected to propel the growth of the molecular oncology diagnostics market over the forecast period.

Market Segmentation:

Segmentation 1: by Product

  • Kits and Assays
  • Instruments
  • Software

Based on product, the kits and assays in the global molecular oncology diagnostics market is expected to dominate by product segment owing to their recurring demand and lower cost.

Segmentation 2: by Technology

  • Polymerase Chain Reaction
  • Next-Generation Sequencing
  • Immunohistochemistry
  • Fluorescence In-Situ Hybridization
  • Flow Cytometry
  • Other Technologies

On the basis of technology, the global molecular oncology diagnostics market is dominated by the polymerase chain reaction segment due to its high sensitivity, accuracy, and cost-effectiveness.

Segmentation 3: by Application

  • Clinical Diagnostics
  • Research Use

Based on application, the global molecular oncology diagnostics market is dominated by the clinical diagnostics. This predominance has been driven by the increasing adoption of precision medicine in healthcare, where molecular diagnostics are integral for identifying specific oncogenic mutations to guide targeted therapy decisions.

Segmentation 4: by Cancer Type

  • Solid Tumors
  • Hematologic Malignancies

Based on cancer type, the global molecular oncology diagnostics market is dominated by the solid tumors. This predominance can be attributed to the higher prevalence of solid tumors, such as breast, lung, and colorectal cancers, compared to hematological malignancies. Solid tumors represent a broad array of the most common cancers, which necessitates extensive diagnostic testing for effective treatment planning, thus driving higher demand for molecular diagnostics within this segment.

Segmentation 5: by End User

  • Hospitals and Diagnostic Centers
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

Based on end user, the global molecular oncology diagnostics market is dominated by the hospitals segment. This is primarily due to hospitals' direct patient care setting, where rapid and accurate diagnostic testing is crucial for timely decision-making in cancer treatment.

Segmentation 6: by Region

  • North America - U.S., and Canada
  • Europe - U.K., Germany, France, Italy, Spain, and Rest-of-Europe
  • Asia-Pacific - Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific
  • Rest-of-the-World

North America generated the highest revenue of $969.6 million in 2023. The molecular oncology diagnostics market in North America is poised for significant growth driven by several key factors. The increasing incidence of cancer across the region is a major driver, with projections indicating a substantial rise in both solid tumors and hematological malignancies by 2050. Moreover, the region benefits from the strong presence of both global and local players, enhancing accessibility to advanced diagnostic technologies.

Recent Developments in the Global Molecular Oncology Diagnostics Market

  • In May 2024, Becton, Dickinson and Company announced that the U.S. Food and Drug Administration (FDA) has approved the use of self-collected vaginal specimens for human papillomavirus (HPV) testing, to be utilized when cervical specimens are not available.
  • In February 2024, Myriad Genetics, Inc. announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in Japan to investigate the prognostic and predictive value of molecular residual disease (MRD) testing. The SCRUM-MONSTAR-SCREEN-3 study will utilize Myriad's ultra-sensitive MRD test, Precise MRD, to monitor circulating tumor DNA (ctDNA) over time in patients with various solid tumors and hematological cancers.
  • In January 2024, Guardant Health and Hikma have partnered to provide cancer screening and comprehensive genomic profiling tests in the Middle East and North Africa.
  • In November 2023, Illumina launched an advanced liquid biopsy assay designed to enable comprehensive genomic profiling of solid tumors.

Demand - Drivers and Limitations

The following are the demand drivers for the global molecular oncology diagnostics market:

  • Rising Incidence of Cancer Cases
  • Rising Technological Advancements in Molecular Diagnostics
  • Growth in Biomarker Identification and Transformation in Molecular Techniques
  • Growing Demand for Personalized Medicine

The market is expected to face some limitations due to the following challenges:

  • Lack of Qualified Professionals
  • High Cost of Molecular Diagnostic Kits and Assays Hindering the Adoption Rate

Key Market Players and Competition Synopsis

The global molecular oncology diagnostics market is expected to witness significant growth, fueled by the increasing incidence of cancer worldwide and the rising demand for personalized medicine. This sector is revolutionizing cancer treatment by enabling precise tumor profiling through advanced technologies such as next-generation sequencing (NGS). These innovations allow for the early detection of cancers and the identification of specific genetic mutations, facilitating tailored therapeutic strategies that enhance treatment efficacy and patient outcomes.

Some of the prominent key players in this market are:

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Biocartis Group NV
  • bioMerieux
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Myriad Genetics, Inc.
  • QIAGEN N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

Scope and Definition

1 Global Molecular Oncology Diagnostics Market: Industry Outlook

  • 1.1 Global Incidence and Prevalence of Cancer (by Cancer Type)
    • 1.1.1 North America
    • 1.1.2 Europe
    • 1.1.3 Asia-Pacific
    • 1.1.4 Rest-of-the-World
  • 1.2 Trends: Current and Future Impact Assessment
    • 1.2.1 Increasing Partnerships among Players
    • 1.2.2 Increasing Launch of Innovative Products and Regulatory Approvals in Molecular Oncology Diagnostics Ecosystem
  • 1.3 Regulatory Landscape
    • 1.3.1 Legal Requirements and Framework in the U.S.
      • 1.3.1.1 FDA Regulation
      • 1.3.1.2 CMS Regulation (Reimbursement Scenario)
    • 1.3.2 Legal Requirements and Framework in Europe
    • 1.3.3 Legal Requirements and Framework in Asia-Pacific
      • 1.3.3.1 China
      • 1.3.3.2 Japan
  • 1.4 Impact of COVID-19 on the Molecular Oncology Diagnostics Market
  • 1.5 Liquid Biopsy-Based Cancer Molecular Diagnostics
  • 1.6 Laboratory-Developed Test (LDT) vs. In-Vitro Diagnostics (IVD)
  • 1.7 Role of Companion Diagnostics in the Molecular Oncology Diagnostics Market
  • 1.8 Market Dynamics
    • 1.8.1 Market Drivers
      • 1.8.1.1 Rising Incidence of Cancer Cases
      • 1.8.1.2 Rising Technological Advancements in Molecular Diagnostics
      • 1.8.1.3 Growth in Biomarker Identification and Transformations in Molecular Techniques
      • 1.8.1.4 Growing Demand for Personalized Medicine
    • 1.8.2 Market Challenges
      • 1.8.2.1 Lack of Qualified Professionals
      • 1.8.2.2 High Cost of Molecular Diagnostic Kits and Assays Hindering the Adoption Rate
    • 1.8.3 Market Opportunities
      • 1.8.3.1 Focus on Reimbursement and Medical Coverage for Molecular Oncology Diagnostics
      • 1.8.3.2 Focus on Next-Generation Ultrasensitive Molecular Diagnostics
      • 1.8.3.3 Increasing Growth Opportunities for Molecular Diagnostics Companies in Emerging Economies

2 Global Molecular Oncology Diagnostics Market (by Product)

  • 2.1 Product Summary
  • 2.2 Kits and Assays
  • 2.3 Instruments
  • 2.4 Software

3 Global Molecular Oncology Diagnostics Market (by Technology)

  • 3.1 Technology Summary
  • 3.2 Polymerase Chain Reaction
  • 3.3 Next-Generation Sequencing
  • 3.4 Immunohistochemistry
  • 3.5 Fluorescence In-Situ Hybridization
  • 3.6 Flow Cytometry
  • 3.7 Other Technologies

4 Global Molecular Oncology Diagnostics Market (by Application)

  • 4.1 Application Summary
  • 4.2 Clinical Diagnostics
  • 4.3 Research Use

5 Global Molecular Oncology Diagnostics Market (by Cancer Type)

  • 5.1 Cancer Type Summary
  • 5.2 Solid Tumors
    • 5.2.1 Breast Cancer
    • 5.2.2 Lung Cancer
    • 5.2.3 Colorectal Cancer
    • 5.2.4 Prostate Cancer
    • 5.2.5 Ovarian Cancer
    • 5.2.6 Other Solid Tumors
  • 5.3 Hematological Malignancies
    • 5.3.1 Lymphoma
    • 5.3.2 Leukemia
    • 5.3.3 Multiple Myeloma
    • 5.3.4 Other Hematological Malignancies

6 Global Molecular Oncology Diagnostic Market (by End User)

  • 6.1 End User Summary
  • 6.2 Hospitals and Diagnostic Centers
  • 6.3 Reference Laboratories
  • 6.4 Pharmaceutical and Biotechnology Companies
  • 6.5 Academic and Research Institutes

7 Global Molecular Oncology Diagnostics Market: by Region

  • 7.1 Regional Summary
  • 7.2 Drivers and Restraints
  • 7.3 North America
    • 7.3.1 Regional Overview
    • 7.3.2 Driving Factors for Market Growth
    • 7.3.3 Factors Challenging the Market
    • 7.3.4 By Cancer Type
    • 7.3.5 By End User
    • 7.3.6 U.S.
      • 7.3.6.1 By Cancer Type
      • 7.3.6.2 By End User
    • 7.3.7 Canada
      • 7.3.7.1 By Cancer Type
      • 7.3.7.2 By End User
  • 7.4 Europe
    • 7.4.1 Regional Overview
    • 7.4.2 Driving Factors for Market Growth
    • 7.4.3 Factors Challenging the Market
    • 7.4.4 By Cancer Type
    • 7.4.5 By End User
    • 7.4.6 Germany
      • 7.4.6.1 By Cancer Type
      • 7.4.6.2 By End User
    • 7.4.7 France
      • 7.4.7.1 By Cancer Type
      • 7.4.7.2 By End User
    • 7.4.8 U.K.
      • 7.4.8.1 By Cancer Type
      • 7.4.8.2 By End User
    • 7.4.9 Italy
      • 7.4.9.1 By Cancer Type
      • 7.4.9.2 By End User
    • 7.4.10 Spain
      • 7.4.10.1 By Cancer Type
      • 7.4.10.2 By End User
    • 7.4.11 Rest-of-Europe
      • 7.4.11.1 By Cancer Type
      • 7.4.11.2 By End User
  • 7.5 Asia-Pacific
    • 7.5.1 Regional Overview
    • 7.5.2 Driving Factors for Market Growth
    • 7.5.3 Factors Challenging the Market
    • 7.5.4 By Cancer Type
    • 7.5.5 By End User
    • 7.5.6 China
      • 7.5.6.1 By Cancer Type
      • 7.5.6.2 By End User
    • 7.5.7 India
      • 7.5.7.1 By Cancer Type
      • 7.5.7.2 By End User
    • 7.5.8 Japan
      • 7.5.8.1 By Cancer Type
      • 7.5.8.2 By End User
    • 7.5.9 South Korea
      • 7.5.9.1 By Cancer Type
      • 7.5.9.2 By End User
    • 7.5.10 Australia
      • 7.5.10.1 By Cancer Type
      • 7.5.10.2 By End User
    • 7.5.11 Rest-of-Asia-Pacific
      • 7.5.11.1 By Cancer Type
      • 7.5.11.2 By End User
  • 7.6 Rest-of-the-World
    • 7.6.1 Regional Overview
    • 7.6.2 Driving Factors for Market Growth
    • 7.6.3 Factors Challenging the Market
    • 7.6.4 By Cancer Type
    • 7.6.5 By End User

8 Global Molecular Oncology Diagnostics Market - Competitive Benchmarking & Company Profiles

  • 8.1 Key Strategic Development
    • 8.1.1 Partnerships, Alliances, and Business Expansions
    • 8.1.2 New Offerings
    • 8.1.3 Mergers and Acquisitions
    • 8.1.4 Regulatory and Legal Activities
  • 8.2 Company Share Analysis
  • 8.3 Company Profiles
    • 8.3.1 Abbott Laboratories
      • 8.3.1.1 Overview
      • 8.3.1.2 Top Products
      • 8.3.1.3 Top Competitors
      • 8.3.1.4 Target Customers/End User
      • 8.3.1.5 Key Personnel
      • 8.3.1.6 Corporate Strategies
      • 8.3.1.7 Analyst View
    • 8.3.2 Agilent Technologies, Inc.
      • 8.3.2.1 Overview
      • 8.3.2.2 Top Products/Product Portfolio
      • 8.3.2.3 Top Competitors
      • 8.3.2.4 Target Customers/End User
      • 8.3.2.5 Key Personnel
      • 8.3.2.6 Analyst View
    • 8.3.3 Biocartis Group NV
      • 8.3.3.1 Overview
      • 8.3.3.2 Top Products
      • 8.3.3.3 Top Competitors
      • 8.3.3.4 Target Customers/End User
      • 8.3.3.5 Key Personnel
      • 8.3.3.6 Analyst View
    • 8.3.4 bioMerieux
      • 8.3.4.1 Overview
      • 8.3.4.2 Top Products
      • 8.3.4.3 Top Competitors
      • 8.3.4.4 Target Customers/End User
      • 8.3.4.5 Key Personnel
      • 8.3.4.6 Analyst View
    • 8.3.5 Bio-Rad Laboratories, Inc.
      • 8.3.5.1 Overview
      • 8.3.5.2 Top Products
      • 8.3.5.3 Top Competitors
      • 8.3.5.4 Target Customers/End User
      • 8.3.5.5 Key Personnel
      • 8.3.5.6 Analyst View
    • 8.3.6 Danaher Corporation
      • 8.3.6.1 Overview
      • 8.3.6.2 Top Products/Product Portfolio
      • 8.3.6.3 Top Competitors
      • 8.3.6.4 Target Customers/End User
      • 8.3.6.5 Key Personnel
      • 8.3.6.6 Analyst View
    • 8.3.7 Exact Sciences Corporation
      • 8.3.7.1 Overview
      • 8.3.7.2 Top Products/Product Portfolio
      • 8.3.7.3 Top Competitors
      • 8.3.7.4 Target Customers/End User
      • 8.3.7.5 Key Personnel
      • 8.3.7.6 Analyst View
    • 8.3.8 F. Hoffmann-La Roche Ltd.
      • 8.3.8.1 Overview
      • 8.3.8.2 Top Products
      • 8.3.8.3 Top Competitors
      • 8.3.8.4 Target Customers/End User
      • 8.3.8.5 Key Personnel
      • 8.3.8.6 Analyst View
    • 8.3.9 Guardant Health, Inc.
      • 8.3.9.1 Overview
      • 8.3.9.2 Top Products
      • 8.3.9.3 Top Competitors
      • 8.3.9.4 Target Customers/End User
      • 8.3.9.5 Key Personnel
      • 8.3.9.6 Analyst View
    • 8.3.10 Hologic, Inc.
      • 8.3.10.1 Overview
      • 8.3.10.2 Top Products
      • 8.3.10.3 Top Competitors
      • 8.3.10.4 Target Customers/End User
      • 8.3.10.5 Key Personnel
      • 8.3.10.6 Analyst View
    • 8.3.11 Illumina, Inc.
      • 8.3.11.1 Overview
      • 8.3.11.2 Top Products
      • 8.3.11.3 Top Competitors
      • 8.3.11.4 Target Customers/End User
      • 8.3.11.5 Key Personnel
      • 8.3.11.6 Analyst View
    • 8.3.12 Invivoscribe, Inc.
      • 8.3.12.1 Overview
      • 8.3.12.2 Top Products
      • 8.3.12.3 Target Competitors
      • 8.3.12.4 Target Customers/End User
      • 8.3.12.5 Key Personnel
      • 8.3.12.6 Analyst View
    • 8.3.13 Myriad Genetics, Inc.
      • 8.3.13.1 Overview
      • 8.3.13.2 Top Products
      • 8.3.13.3 Top Competitors
      • 8.3.13.4 Target Customers/End User
      • 8.3.13.5 Key Personnel
      • 8.3.13.6 Analyst View
    • 8.3.14 QIAGEN N.V.
      • 8.3.14.1 Overview
      • 8.3.14.2 Top Products
      • 8.3.14.3 Top Competitors
      • 8.3.14.4 Target Customers/End User
      • 8.3.14.5 Key Personnel
      • 8.3.14.6 Analyst View
    • 8.3.15 Sysmex Corporation
      • 8.3.15.1 Overview
      • 8.3.15.2 Top Products
      • 8.3.15.3 Top Competitors
      • 8.3.15.4 Target Customers/End User
      • 8.3.15.5 Key Personnel
      • 8.3.15.6 Analyst View
    • 8.3.16 Thermo Fisher Scientific, Inc.
      • 8.3.16.1 Overview
      • 8.3.16.2 Top Products
      • 8.3.16.3 Top Competitors
      • 8.3.16.4 Target Customers/End User
      • 8.3.16.5 Key Personnel
      • 8.3.16.6 Analyst View

9 Research Methodology

  • 9.1 Data Sources
    • 9.1.1 Primary Data Sources
    • 9.1.2 Secondary Data Sources
    • 9.1.3 Data Triangulation
  • 9.2 Market Estimation and Forecast

List of Figures

  • Figure 1 Global Molecular Oncology Diagnostics Market, $Million, 2024, 2028, and 2033
  • Figure 2 Global Molecular Oncology Diagnostics Market (by Region), $Million, 2023, 2027, and 2033
  • Figure 3 Global Molecular Oncology Diagnostics Market (by Product), $Million, 2023, 2027, and 2033
  • Figure 4 Global Molecular Oncology Diagnostics Market (by Application), $Million, 2023, 2027, and 2033
  • Figure 5 Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2023, 2027, and 2033
  • Figure 6 Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023, 2027, and 2033
  • Figure 7 Global Molecular Oncology Diagnostics Market (by End User), $Million, 2023, 2027, and 2033
  • Figure 8 Role of Diagnostics in Healthcare
  • Figure 9 Cancer Prevalence and Incidence (by Cancer Type), in Million, North America, 2022
  • Figure 10 Cancer Prevalence and Incidence (by Cancer Type), in Million, Europe, 2022
  • Figure 11 Cancer Prevalence and Incidence (by Cancer Type), in Million, Asia-Pacific, 2022
  • Figure 12 Cancer Prevalence and Incidence (by Cancer Type), in Million, Rest-of-the-World, 2022
  • Figure 13 FDA Guidelines for CDx Approval
  • Figure 14 Criteria for CMS Coverage/Reimbursement
  • Figure 15 Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
  • Figure 16 Workflow for Medical Device Regulations
  • Figure 17 Technological Advances in Liquid Biopsy Analysis
  • Figure 18 List of Some Liquid Biopsy-Based Available Tests Approved by FDA/CE-IVD
  • Figure 19 Prominent FDA-Approved Companion Diagnostics
  • Figure 20 Impact Analysis of Market Navigating Factors, 2022-2033
  • Figure 21 Global Distribution of Cases and Deaths (by Cancer Type), 2022
  • Figure 22 Global Incidence for Cancer Types, 2018-2022
  • Figure 23 U.S. Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 24 Canada Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 25 Germany Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 26 France Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 27 U.K. Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 28 Italy Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 29 Spain Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 30 Rest-of-Europe Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 31 China Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 32 India Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 33 Japan Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 34 South Korea Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 35 Australia Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 36 Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 37 Partnerships, Alliances, and Business Expansions, January 2021-July 2024
  • Figure 38 New Offerings, January 2021-July 2024
  • Figure 39 Mergers and Acquisitions, January 2021-July 2024
  • Figure 40 Regulatory and Legal Activities, January 2021-July 2024
  • Figure 41 Data Triangulation
  • Figure 42 Top-Down and Bottom-Up Approach
  • Figure 43 Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Key Trends, Impact Analysis
  • Table 3: Global Molecular Oncology Diagnostics Market, Partnerships and Collaborations
  • Table 4: Global Molecular Oncology Diagnostics Market, Product Launches and Regulatory Approvals
  • Table 5: Global Molecular Oncology Diagnostics Market, New Offerings
  • Table 6: Biomarkers for Different Cancer Types
  • Table 7: Significance of Different Biomarkers in Clinical Outcomes of Various Cancer
  • Table 8: Cost of Liquid Biopsy-Based NGS Kits
  • Table 9: Global Molecular Oncology Diagnostics Market, Reimbursement and Medical Coverage
  • Table 10: Global Molecular Oncology Diagnostics Market (by Product), $Million, 2023-2033
  • Table 11: Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2023-2033
  • Table 12: Global Molecular Oncology Diagnostics Market (by Offering), $Million, 2023-2033
  • Table 13: Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 14: Global Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 15: Global Molecular Oncology Diagnostics Market Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 16: Global Molecular Oncology Diagnostics Market (by End User, $Million, 2023-2033
  • Table 17: Global Molecular Oncology Diagnostics Market (by Region), $Million, 2023-2033
  • Table 18: North America Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 19: North America Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 20: North America Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 21: North America Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 22: U.S. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 23: U.S. Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 24: U.S. Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 25: U.S. Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 26: Canada Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 27: Canada Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 28: Canada Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 29: Canada Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 30: Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 31: Europe Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 32: Europe Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 33: Europe Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 34: Germany Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 35: Germany Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 36: Germany Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 37: Germany Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 38: France Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 39: France Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 40: France Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 41: France Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 42: U.K. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 43: U.K. Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 44: U.K. Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 45: U.K. Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 46: Italy Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 47: Italy Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 48: Italy Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 49: Italy Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 50: Spain Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 51: Spain Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 52: Spain Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 53: Spain Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 54: Rest-of-Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 55: Rest-of-Europe Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 56: Rest-of-Europe Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 57: Rest-of-Europe Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 58: Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 59: Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 60: Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 61: Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 62: China Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 63: China Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 64: China Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 65: China Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 66: India Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 67: India Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 68: India Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 69: India Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 70: Japan Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 71: Japan Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 72: Japan Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 73: Japan Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 74: South Korea Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 75: South Korea Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 76: South Korea Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 77: South Korea Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 78: Australia Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 79: Australia Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 80: Australia Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 81: Australia Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 82: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 83: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 84: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 85: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 86: Rest-of-the-World Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 87: Rest-of-the-World Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 88: Rest-of-the-World Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 89: Rest-of-the-World Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 90: Global Molecular Oncology Diagnostics Market, Company Share Analysis, 2023